MATTERHORN: Durvalumab plus FLOT improves OS in patients with resectable gastric and gastroesophageal junction adenocarcinoma

CHICAGO 2025

Gastrointestinal Cancer

LBA5: MATTERHORN: Adding durvalumab to chemotherapy improves EFS in resectable gastric and gastroesophageal junction adenocarcinoma

Gastrointestinal Cancer

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer

N Engl J Med

Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Garrido M, Oliveira SCS, Liberman M, Oliden VC, Smyth EC, Stein A, Bilici M, Alvarenga ML, Kozlov V, Rivera F, Kawazoe A, Serrano O, Heilbron E, Negro A, Kurland JF, Tabernero J, MATTERHORN Investigators

doi: 10.1056/NEJMoa2503701

Gastrointestinal Cancer

Adjuvant FLOT provides survival benefit for oesophagogastric junction and gastric adenocarcinoma patients with low tumour regression after neoadjuvant chemotherapy

Int J Cancer

Kraemer M, Wirsik NM, Alakus H, Schloesser HA, Fuchs H, Schroeder W, Bruns CJ, Lyu SI, Baehr F, Zander T, Quaas A

doi: 10.1002/ijc.70048

CHICAGO 2025

Gastrointestinal Cancer

LBA4002: DESTINY-Gastric04: Improved OS with second-line T-Dxd versus ramucirumab plus paclitaxel in patients with HER2-positive metastatic GC/GEJA

ESMO 2025

Genitourinary Cancer

POTOMAC: Durvalumab plus BCG significantly improves DFS in patients with high-risk NMIBC

ELCC 2025

Lung, Respiratory and Thoracic Cancer

SAKK 16/14: Adding durvalumab to neoadjuvant chemotherapy achieves encouraging EFS and OS in patients with resectable stage IIIA(N2) NSCLC

Gastrointestinal Cancer

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study

J Clin Oncol

Shitara K, Rha SY, Wyrwicz L, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusaki H, Afanasyev S, Park YK, Al-Batran SE, Yoshikawa T, Yanez P, Pietrantonio F, Lonardi S, Fang X, Guan Y, Valderrama A, Leconte P, Bhagia P, Bang YJ, KEYNOTE-585 Investigators

doi: 10.1200/JCO-25-00486

ELCC 2025

Lung, Respiratory and Thoracic Cancer

MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC

CHICAGO 2025

Gastrointestinal Cancer

Related content

LBA5: MATTERHORN: Adding durvalumab to chemotherapy improves EFS in resectable gastric and gastroesophageal junction adenocarcinoma

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer

Adjuvant FLOT provides survival benefit for oesophagogastric junction and gastric adenocarcinoma patients with low tumour regression after neoadjuvant chemotherapy

LBA4002: DESTINY-Gastric04: Improved OS with second-line T-Dxd versus ramucirumab plus paclitaxel in patients with HER2-positive metastatic GC/GEJA

POTOMAC: Durvalumab plus BCG significantly improves DFS in patients with high-risk NMIBC

SAKK 16/14: Adding durvalumab to neoadjuvant chemotherapy achieves encouraging EFS and OS in patients with resectable stage IIIA(N2) NSCLC

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study

MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC

BREAKWATER: Encorafenib plus cetuximab and mFOLFOX6 improves PFS and OS in treatment-naïve patients with BRAF V600E-mutant mCRC